Meeting
2020 ASCO Virtual Scientific Program
Gene signature of antigen processing and presentation machinery (APM) as highly predictive of response to checkpoint blockade in lung cancer and melanoma.
Authors
Jeffrey C. Thompson
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
Jeffrey C. Thompson , Christiana Davis , Wei-Ting Hwang , Charuhas Deshpande , Seth Jeffries , Corey J. Langer , Steven M. Albelda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3121)
DOI
10.1200/JCO.2020.38.15_suppl.3121
Abstract #
3121
Poster Bd #
185
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Revisiting the optimal neoadjuvant immunotherapy regimen in resectable stage III melanoma based on the interferon gamma signature: A pooled analysis.
First Author: Minke W. Lucas
Poster
2023 ASCO Annual Meeting
A pilot study of the neoadjuvant use of vemurafenib plus cobimetinib in patients with BRAF-mutant melanoma with palpable lymph node metastases: Survival results.
First Author: Teresa M. Petrella
Poster
2023 ASCO Annual Meeting
Comparing the impact of steroid sparing immunosuppression vs. steroid monotherapy for immune-related adverse events in non–small cell lung cancer and melanoma.
First Author: Sharjeel Syed
Poster
2023 ASCO Annual Meeting
Real-world outcomes of patients (pts) with malignant solid tumors treated with immune checkpoint inhibitors (ICI) in relation to smoking status: The SAKK 80/19 SMOKER study.
First Author: Tämer El Saadany